{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:39:06Z","timestamp":1794634746508,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The relationship between tumour necrosis factor-alpha inhibitors (TNFis) and cancer risk is complex, given their pivotal role in managing chronic inflammatory conditions. Persistent concerns about TNFi therapy potentially increasing cancer risk necessitate a thorough understanding of its long-term effects on cancer development in patients with psoriasis to guide therapeutic decision making.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the association between long-term TNFi therapy and cancer risk in patients with psoriasis in a systematic review and meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected from PubMed, Embase and the Cochrane Library, from their inception to 1 January 2024. The studies included adults with psoriasis or psoriatic arthritis receiving an TNFi, presenting standardized incidence ratio (SIR) data for cancer. Data extraction followed PRISMA guidelines, with independent extraction by two authors, and pooled data synthesis was conducted using a random-effects model. The primary outcomes were SIRs for all cancers excluding nonmelanoma skin carcinoma (NMSC) and for NMSC itself. The secondary outcome was SIRs for specific cancer types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We reviewed 13 studies, including 8 new studies and 5 from a previous meta-analysis. Of the 13 studies, only 8 were included in the meta-analysis comprising a total of 32 765 patients with psoriasis. The pooled results showed no increased risk of cancers for the categories: all cancers excluding NMSC; melanoma; lymphoma; prostate cancer; and breast cancer among individuals receiving long-term TNFi therapy for psoriasis compared with the general population. However, subgroup analysis found an elevated risk of NMSC in patients with psoriatic arthritis and a significant increase in the risk of squamous cell carcinoma (SCC) among patients with psoriasis treated with TNFis compared with the general population [SIR 1.84, 95% confidence interval (CI) 1.16\u20132.92 and SIR 2.84, 95% CI 1.64\u20134.91, respectively].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our systematic review and meta-analysis indicate that most cancers examined did not demonstrate an increased risk following long-term TNFi therapy in patients with psoriasis. However, for patients with psoriatic arthritis or those at high risk of SCC, these findings underscore the importance of personalized treatment strategies that weigh individual risks and benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae503","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T01:15:18Z","timestamp":1732842918000},"page":"968-980","source":"Crossref","is-referenced-by-count":9,"title":["The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a\u202fsystematic review and meta-analysis"],"prefix":"10.1093","volume":"50","author":[{"given":"Wen-Ting","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2350-4634","authenticated-orcid":false,"given":"Ming-Che","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]},{"name":"Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University , Taipei ,","place":["Taiwan"]},{"name":"Research Center of Big Data and Meta-analysis, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2025042411072925200_llae503-B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2025042411072925200_llae503-B2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic burden of psoriasis in the United States","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025042411072925200_llae503-B3","doi-asserted-by":"crossref","first-page":"11574","DOI":"10.3390\/ijms222111574","article-title":"Current concepts of psoriasis immunopathogenesis","volume":"22","author":"Vi\u010di\u0107","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025042411072925200_llae503-B4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411072925200_llae503-B5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025042411072925200_llae503-B6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025042411072925200_llae503-B7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/jdv.12001","article-title":"Obesity, waist circumference, weight change and the risk of psoriasis in US women","volume":"27","author":"Kumar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411072925200_llae503-B8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2017.04.015","article-title":"Smoking and risk of psoriasis: a nationwide cohort study","volume":"77","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.21718","article-title":"Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study","volume":"187","author":"Wei","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025042411072925200_llae503-B10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411072925200_llae503-B11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/phpp.12382","article-title":"Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy: a 15-year experience from our Institute","volume":"34","author":"Raone","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2025042411072925200_llae503-B12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025042411072925200_llae503-B13","doi-asserted-by":"crossref","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"2025042411072925200_llae503-B14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025042411072925200_llae503-B15","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1136\/ard.2008.102103","article-title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases","volume":"68","author":"Burmester","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025042411072925200_llae503-B16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","article-title":"Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis","volume":"37","author":"Burmester","year":"2020","journal-title":"Adv Ther"},{"issue":"Suppl. 1","key":"2025042411072925200_llae503-B17","first-page":"i135","article-title":"Risk of cancer in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition","volume":"54","author":"Fagerli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025042411072925200_llae503-B18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025042411072925200_llae503-B19","first-page":"289","article-title":"Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications","volume":"10","author":"Gottlieb","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"2025042411072925200_llae503-B20","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/rheumatology\/keaa828","article-title":"Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors \u2013 a Nordic cohort study","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025042411072925200_llae503-B21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjd.17084","article-title":"Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis","volume":"180","author":"Leonardi","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025042411072925200_llae503-B22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50\u2005mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"2025042411072925200_llae503-B23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025042411072925200_llae503-B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","volume":"72","author":"Kimball","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"2025042411072925200_llae503-B26","first-page":"1137","article-title":"Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations","volume":"7","author":"Menter","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"2025042411072925200_llae503-B27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2025042411072925200_llae503-B29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fonc.2020.00584","article-title":"Tumor necrosis factor \u03b1 blockade: an opportunity to tackle breast cancer","volume":"10","author":"Mercogliano","year":"2020","journal-title":"Front Oncol"},{"key":"2025042411072925200_llae503-B30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1185\/03007995.2015.1011778","article-title":"Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk","volume":"31","author":"Lebrec","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2025042411072925200_llae503-B31","doi-asserted-by":"crossref","first-page":"104507","DOI":"10.1016\/j.phrs.2019.104507","article-title":"Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis","volume":"158","author":"Marino","year":"2020","journal-title":"Pharmacol Res"},{"key":"2025042411072925200_llae503-B32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheumat Dis"},{"key":"2025042411072925200_llae503-B33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?","volume":"101","author":"Chen","year":"2018","journal-title":"Cytokine"},{"key":"2025042411072925200_llae503-B34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis","volume":"30","author":"D'Arcy","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025042411072925200_llae503-B35","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025042411072925200_llae503-B36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11739-015-1270-0","article-title":"Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience","volume":"11","author":"Fant\u00f2","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2025042411072925200_llae503-B37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025042411072925200_llae503-B38","doi-asserted-by":"crossref","first-page":"110464","DOI":"10.1016\/j.intimp.2023.110464","article-title":"Psoriasis and skin cancer \u2013 is there a link?","volume":"121","author":"Balda","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025042411072925200_llae503-B39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/jca.37015","article-title":"Risk of non-melanoma skin cancer in patients with psoriasis: an updated evidence from systematic review with meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"2025042411072925200_llae503-B40","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","article-title":"Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study","volume":"149","author":"Jung","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025042411072925200_llae503-B41","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/life11101109","article-title":"Psoriasis therapy and skin cancer: a review","volume":"11","author":"Butr\u00f3n-Bris","year":"2021","journal-title":"Life"},{"key":"2025042411072925200_llae503-B42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411072925200_llae503-B43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2340\/00015555-1753","article-title":"The risk of skin cancer in psoriasis patients treated with UVB therapy","volume":"94","author":"Osmancevic","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2025042411072925200_llae503-B44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan","volume":"65","author":"Chen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025042411072925200_llae503-B46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025042411072925200_llae503-B47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B48","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case\u2013control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2025042411072925200_llae503-B49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1067\/mjd.2001.114742","article-title":"Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996","volume":"45","author":"Harris","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2025042411072925200_llae503-B50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archderm.1997.03890420073008","article-title":"Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992","volume":"133","author":"Gray","year":"1997","journal-title":"Arch Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae503\/60898334\/llae503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/968\/60898334\/llae503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/968\/60898334\/llae503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:07:42Z","timestamp":1745507262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/5\/968\/7912532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae503","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,11,29]]}}}